Marianne T Severinsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7658079/publications.pdf

Version: 2024-02-01

91 papers 2,336 citations

23 h-index

279778

223791 46 g-index

94 all docs

94 docs citations 94 times ranked 4051 citing authors

#	Article	IF	CITATIONS
1	Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Journal of Clinical Oncology, 2015, 33, 3641-3649.	1.6	340
2	Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. Journal of Clinical Epidemiology, 2010, 63, 223-228.	5.0	188
3	Anthropometry, Body Fat, and Venous Thromboembolism. Circulation, 2009, 120, 1850-1857.	1.6	120
4	Smoking and venous thromboembolism: a Danish follow-up study. Journal of Thrombosis and Haemostasis, 2009, 7, 1297-1303.	3.8	118
5	Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2394-2403.	5.1	118
6	Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism. Circulation, 2017, 135, 7-16.	1.6	114
7	Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish populationâ€based cohort study. British Journal of Haematology, 2011, 152, 360-362.	2.5	113
8	Body Size and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3252-3261.	2.5	104
9	Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica, 2008, 93, 1666-1677.	3.5	78
10	Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2404-2415.	5.1	68
11	Body height and sex-related differences in incidence of venous thromboembolism: A Danish follow-up study. European Journal of Internal Medicine, 2010, 21, 268-272.	2.2	63
12	Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia, 2015, 29, 548-555.	7.2	57
13	Data quality in the Danish National Acute Leukemia Registry: a hematological data resource. Clinical Epidemiology, 2013, 5, 335.	3.0	48
14	Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish populationâ€based cohort study. British Journal of Haematology, 2012, 159, 109-111.	2.5	45
15	Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. British Journal of Haematology, 2010, 149, 273-279.	2.5	43
16	The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. Journal of Thrombosis and Haemostasis, 2017, 15, 1567-1575.	3.8	39
17	Impact of Incident Venous Thromboembolism on Risk of Arterial Thrombotic Diseases. Circulation, 2014, 129, 855-863.	1.6	38
18	Alcohol intake and risk of venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 39-45.	3.4	34

#	Article	IF	CITATIONS
19	Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study. Journal of Clinical Oncology, 2017, 35, 3678-3687.	1.6	30
20	Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. European Journal of Haematology, 2011, 86, 129-134.	2.2	29
21	Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations. Oncotarget, 2016, 7, 9951-9963.	1.8	27
22	Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish caseâ€cohort study. British Journal of Haematology, 2013, 160, 838-841.	2.5	26
23	The Danish National Acute Leukemia Registry. Clinical Epidemiology, 2016, Volume 8, 553-560.	3.0	26
24	R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. Leukemia and Lymphoma, 2017, 58, 1105-1113.	1.3	26
25	Genomic profiling of a randomized trial of interferon- \hat{l}_{\pm} vs hydroxyurea in MPN reveals mutation-specific responses. Blood Advances, 2022, 6, 2107-2119.	5.2	26
26	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Advances, 2022, 6, 2967-2976.	5.2	23
27	SARSâ€CoVâ€2 infection among patients with haematological disorders: Severity and oneâ€month outcome in 66 Danish patients in a nationwide cohort study. European Journal of Haematology, 2021, 106, 72-81.	2.2	21
28	Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clinical Epidemiology, 2015, 7, 401.	3.0	20
29	Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 2771-2776.	1.3	20
30	Epidemiology of venous thromboembolism in hematological cancers: The Scandinavian Thrombosis and Cancer (STAC) cohort. Thrombosis Research, 2017, 158, 157-160.	1.7	19
31	Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national populationâ€based caseâ€control study. British Journal of Haematology, 2018, 181, 205-214.	2.5	18
32	Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients. Oncotarget, 2016, 7, 72044-72056.	1.8	18
33	Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. Leukemia and Lymphoma, 2020, 61, 1345-1354.	1.3	16
34	Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. Blood, 2018, 132, 580-580.	1.4	14
35	Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review. Leukemia and Lymphoma, 2019, 60, 3116-3131.	1.3	13
36	Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. Cancer Medicine, 2020, 9, 4395-4404.	2.8	13

#	Article	IF	Citations
37	On estimating the time to statistical cure. BMC Medical Research Methodology, 2020, 20, 71.	3.1	12
38	Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor NaÃ-ve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients. Blood, 2020, 136, 51-52.	1.4	12
39	Fish intake and venous thromboembolism: A Danish follow-up study. Thrombosis Research, 2014, 133, 352-356.	1.7	10
40	The prognostic effect of smoking status on intensively treated acute myeloid leukaemia – A Danish nationwide cohort study. British Journal of Haematology, 2020, 190, 236-243.	2.5	10
41	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. Journal of Clinical Oncology, 2021, 39, 3463-3472.	1.6	10
42	Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study. Blood Advances, 2018, 2, 3025-3034.	5.2	9
43	Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis. Journal of Fungi (Basel, Switzerland), 2020, 6, 268.	3.5	9
44	Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000–2016: a Danish populationâ€based study. British Journal of Haematology, 2021, 193, 482-487.	2.5	9
45	Venous thromboembolism after lower extremity orthopedic surgery: A populationâ€based nationwide cohort study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 148-158.	2.3	9
46	Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study. Blood Advances, 2018, 2, 559-564.	5.2	8
47	Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. Cancers, 2020, 12, 312.	3.7	8
48	Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation. Experimental Hematology, 2018, 68, 62-65.	0.4	7
49	Cancer Risk and Prognosis after a Hospital Contact for an Elevated Erythrocyte Sedimentation Rate. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 225-232.	2.5	6
50	A randomised evaluation of lowâ€dose cytosine arabinoside (ara) plus tosedostat <i>versus</i> lowâ€dose ara in older patients with acute myeloid leukaemia: results of the Llâ€1 trial. British Journal of Haematology, 2021, 194, 298-308.	2.5	6
51	Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort. Scientific Reports, 2021, 11, 18752.	3.3	6
52	Extramedullary Leukemia and Myeloid Sarcoma in AML: Results From a Population-Based Registry Study of 2261 Patients. Blood, 2011, 118, 2003-2003.	1.4	6
53	Mental health among patients with nonâ€Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators. American Journal of Hematology, 2022, 97, 749-761.	4.1	6
54	Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study. Blood, 2018, 131, 2730-2733.	1.4	5

#	Article	IF	CITATIONS
55	Addressing the room for improvement in management of acute promyelocytic leukemia. European Journal of Haematology, 2019, 102, 479-485.	2.2	5
56	The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clinical Epidemiology, 2021, Volume 13, 439-451.	3.0	5
57	Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study. Leukemia, 2018, 32, 2263-2303.	7.2	4
58	Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open, 2018, 02, e131-e138.	1.4	4
59	Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. Clinical Epidemiology, 2019, Volume 11, 769-780.	3.0	4
60	Prothrombotic genotypes and risk of venous thromboembolism in occult cancer. Thrombosis Research, 2021, 205, 17-23.	1.7	4
61	Exhaled breath condensate in acute pulmonary embolism; a porcine study of effect of condensing temperature and feasibility of protein analysis by mass spectrometry. Journal of Breath Research, 2021, 15, 026005.	3.0	4
62	Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia. Journal of Hematology (Brossard, Quebec), 2020, 9, 89-92.	1.0	4
63	A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment. Blood Advances, 2022, 6, 2549-2556.	5.2	4
64	Survival of cancer patients with prior monoclonal gammopathy of undetermined significance. European Journal of Internal Medicine, 2010, 21, 564-568.	2.2	3
65	Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. PLoS ONE, 2020, 15, e0229593.	2.5	3
66	Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001â€"2016: a Danish nationwide cohort study. Leukemia and Lymphoma, 2021, 62, 2014-2017.	1.3	3
67	A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia. Leukemia Research, 2022, 112, 106756.	0.8	3
68	Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. Blood Cancer Journal, 2022, 12, 16.	6.2	3
69	OPTIC-2L: a Superiority Trial of Two Lower Doses of Ponatinib Versus Standard Dose Nilotinib in Second-Line Chronic Phase CML. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S60-S61.	0.4	2
70	Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission. Experimental Hematology and Oncology, 2017, 6, 3.	5.0	2
71	Anthropometrics and prognosis in diffuse large Bâ€cell lymphoma: a multicentre study of 653 patients. European Journal of Haematology, 2017, 98, 355-362.	2.2	2
72	Epidemiology of Venous Thromboembolism After Second Cancer. Clinical Epidemiology, 2020, Volume 12, 377-386.	3.0	2

#	Article	IF	CITATIONS
73	The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy $\hat{a}\in A$ Danish nationwide cohort study. Leukemia Research, 2021, 106, 106567.	0.8	2
74	Validation of Postsurgical Venous Thromboembolism Diagnoses of Patients Undergoing Lower Limb Orthopedic Surgery in the Danish National Patient Registry. Clinical Epidemiology, 2022, Volume 14, 191-199.	3.0	2
75	Response to Letter Regarding Article, "lmpact of Incident Venous Thromboembolism on Risk of Arterial Thrombotic Diseases― Circulation, 2014, 130, e184-5.	1.6	1
76	NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. Cancer Management and Research, 2018, Volume 10, 5043-5051.	1.9	1
77	Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region. BMC Health Services Research, 2020, 20, 1047.	2.2	1
78	Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response. Blood, 2019, 134, 4202-4202.	1.4	1
79	No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study. Blood, 2015, 126, 5177-5177.	1.4	1
80	Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study. Health and Quality of Life Outcomes, 2021, 19, 251.	2.4	1
81	Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders. Acta Oncol $ ilde{A}^3$ gica, 2022, 61, 500-504.	1.8	1
82	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer, 2022, 22, 147.	2.6	1
83	Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients. Clinical Epidemiology, 2022, Volume 14, 225-237.	3.0	1
84	No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients. Leukemia and Lymphoma, 2019, 60, 2798-2801.	1.3	O
85	Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. Future Oncology, 2021, 17, 3331-3341.	2.4	O
86	High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study. Blood, 2012, 120, 3542-3542.	1.4	O
87	Human MICL Is An Early Marker In Myeloid Differentiation and Identifies a Subgroup Of CML Patients With Expanded Granulocyte-Macrophage Progenitor Populations At Diagnosis. Blood, 2013, 122, 2704-2704.	1.4	O
88	From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival. Blood, 2018, 132, 794-794.	1.4	O
89	Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients. Blood, 2019, 134, 2841-2841.	1.4	O
90	Labor Market Attachment in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study. Blood, 2021, 138, 3627-3627.	1.4	0

 #	Article	lF	CITATIONS
91	Risk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy. Blood Advances, 0, , .	5.2	0